These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36127254)

  • 21. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.
    Mueller-Lisse UG; Mueller-Lisse UL; Haller S; Schneede P; Scheidler JE; Schmeller N; Hofstetter AG; Reiser MF
    J Comput Assist Tomogr; 2002; 26(3):432-7. PubMed ID: 12016375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
    Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
    Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
    Numao N; Yoshida S; Komai Y; Ishii C; Kagawa M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Aug; 190(2):502-8. PubMed ID: 23473904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer on computed tomography: A direct comparison with multi-parametric magnetic resonance imaging and tissue pathology.
    Jia JB; Houshyar R; Verma S; Uchio E; Lall C
    Eur J Radiol; 2016 Jan; 85(1):261-267. PubMed ID: 26526901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population.
    Fascelli M; Rais-Bahrami S; Sankineni S; Brown AM; George AK; Ho R; Frye T; Kilchevsky A; Chelluri R; Abboud S; Siddiqui MM; Merino MJ; Wood BJ; Choyke PL; Pinto PA; Turkbey B
    Urology; 2016 Feb; 88():125-34. PubMed ID: 26680244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
    JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging.
    Tamada T; Sone T; Higashi H; Jo Y; Yamamoto A; Kanki A; Ito K
    AJR Am J Roentgenol; 2011 Sep; 197(3):664-70. PubMed ID: 21862809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study.
    Pantelidou M; Caglic I; George A; Blyuss O; Gnanapragasam VJ; Barrett T
    PLoS One; 2022; 17(9):e0274014. PubMed ID: 36084119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
    Bhat NR; Vetter JM; Andriole GL; Shetty AS; Ippolito JE; Kim EH
    Urology; 2019 Apr; 126():152-157. PubMed ID: 30580005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results.
    Bhatia C; Phongkitkarun S; Booranapitaksonti D; Kochakarn W; Chaleumsanyakorn P
    J Med Assoc Thai; 2007 Jul; 90(7):1391-9. PubMed ID: 17710982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermediate-term oncological outcomes after a negative endorectal coil multiparametric MRI of the prostate in patients without biopsy proven prostate cancer.
    Kamal O; Comerford J; Foster BR; Young DJ; Amling C; Coakley FV
    Clin Imaging; 2022 Dec; 92():112-116. PubMed ID: 36306588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.
    Lee SM; Liyanage SH; Wulaningsih W; Wolfe K; Carr T; Younis C; Van Hemelrijck M; Popert R; Acher P
    Urol Oncol; 2017 Nov; 35(11):664.e11-664.e18. PubMed ID: 28801025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study.
    Amsellem-Ouazana D; Younes P; Conquy S; Peyromaure M; Flam T; Debré B; Zerbib M
    Eur Urol; 2005 May; 47(5):582-6. PubMed ID: 15826747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Usefulness of MRI prior to prostate needle biopsy in PSA gray zone].
    Sakura Y; Mishina M; Masui K; Masuda N; Katoh T; Ito H; Yoshida T; Soma T; Dodo T; Nakajima S; Ito T; Okuno H
    Hinyokika Kiyo; 2011 Oct; 57(10):545-9. PubMed ID: 22089151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging.
    Beyersdorff D; Taupitz M; Winkelmann B; Fischer T; Lenk S; Loening SA; Hamm B
    Radiology; 2002 Sep; 224(3):701-6. PubMed ID: 12202702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection.
    Perdonà S; Di Lorenzo G; Autorino R; Buonerba C; De Sio M; Setola SV; Fusco R; Ronza FM; Caraglia M; Ferro M; Petrillo A
    Urol Oncol; 2013 Aug; 31(6):761-5. PubMed ID: 21906966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.
    MacAskill F; Lee SM; Eldred-Evans D; Wulaningsih W; Popert R; Wolfe K; Van Hemelrijck M; Rottenberg G; Liyanage SH; Acher P
    Int Urol Nephrol; 2017 Aug; 49(8):1335-1342. PubMed ID: 28477301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive MRI-TRUS fusion-targeted prostate biopsy according to PI-RADS classification in patients with prior negative systematic biopsy results.
    Lai WJ; Wang HK; Liu HT; Park BK; Shen SH; Lin TP; Chung HJ; Huang YH; Chang YH
    J Chin Med Assoc; 2016 Nov; 79(11):618-624. PubMed ID: 27567440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.